Nomogram for the personalisation of radiotherapy treatments in breast cancer patients

Introduction: Numerous prospective studies have shown that the incorporation of genomic assays into clinical practice significantly impacts the choice of adjuvant treatments for patients with early-stage breast cancer. However, the same evidence does not exist for the treatment of locoregional recur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cáncer de mama Breast cancer Plataformas genómicas Genetic assays Recaída local Local relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/34a937695973461ca48aa7a034ba64b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34a937695973461ca48aa7a034ba64b6
record_format	dspace
spelling	oai:doaj.org-article:34a937695973461ca48aa7a034ba64b62021-11-22T04:18:02ZNomogram for the personalisation of radiotherapy treatments in breast cancer patients1532-308010.1016/j.breast.2021.11.004https://doaj.org/article/34a937695973461ca48aa7a034ba64b62021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0960977621009863https://doaj.org/toc/1532-3080Introduction: Numerous prospective studies have shown that the incorporation of genomic assays into clinical practice significantly impacts the choice of adjuvant treatments for patients with early-stage breast cancer. However, the same evidence does not exist for the treatment of locoregional recurrences. Hypothesis and objectives: The main objective of this work was to identify the clinicopathological, molecular, and genetic parameters that allow patients to be more precisely categorised into risk groups, in order to create a locoregional recurrence riskclassification tool, the PersonalRT27. Material and methods: To create PersonalRT27, we retrospective assessed the variables of patients with early breast cancer (stages I or II) who had undergone the OncotypeDx ® and MammaPrint ® genetic tests. These variables and factors included in the tests were categorised and weighted to obtain scores between 1 and 5 pointsto represent a lower or higher risk of relapse, respectively, based on these factors and as determined by the researchers. Results: The mean follow-up time was 60.5 months (range 25–96 months); locoregional progression-free survival at the time of the analysis was 98.4%, and overall survival was 97.5%, of which 0.6% of the deaths had been cancer specific. The area under the curve for the PersonalRT27 was 0.76 (95% CI [0.70, 0.81]), sensitivity was 78%, and the specificity was 58.9%. We used these factors to create an inhospital web-based nomogram. Conclusions: The PersonalRT27 is a novel tool that integrates clinical-pathological, molecular, and genetic parameters. External and independent validation will be required to implement its clinical use.Inmaculada Beato TortajadaCarlos Ferrer AlbiachVirginia Morillo MaciasElsevierarticleCáncer de mamaBreast cancerPlataformas genómicasGenetic assaysRecaída localLocal relapseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast, Vol 60, Iss , Pp 255-262 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cáncer de mama Breast cancer Plataformas genómicas Genetic assays Recaída local Local relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Cáncer de mama Breast cancer Plataformas genómicas Genetic assays Recaída local Local relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Inmaculada Beato Tortajada Carlos Ferrer Albiach Virginia Morillo Macias Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
description	Introduction: Numerous prospective studies have shown that the incorporation of genomic assays into clinical practice significantly impacts the choice of adjuvant treatments for patients with early-stage breast cancer. However, the same evidence does not exist for the treatment of locoregional recurrences. Hypothesis and objectives: The main objective of this work was to identify the clinicopathological, molecular, and genetic parameters that allow patients to be more precisely categorised into risk groups, in order to create a locoregional recurrence riskclassification tool, the PersonalRT27. Material and methods: To create PersonalRT27, we retrospective assessed the variables of patients with early breast cancer (stages I or II) who had undergone the OncotypeDx ® and MammaPrint ® genetic tests. These variables and factors included in the tests were categorised and weighted to obtain scores between 1 and 5 pointsto represent a lower or higher risk of relapse, respectively, based on these factors and as determined by the researchers. Results: The mean follow-up time was 60.5 months (range 25–96 months); locoregional progression-free survival at the time of the analysis was 98.4%, and overall survival was 97.5%, of which 0.6% of the deaths had been cancer specific. The area under the curve for the PersonalRT27 was 0.76 (95% CI [0.70, 0.81]), sensitivity was 78%, and the specificity was 58.9%. We used these factors to create an inhospital web-based nomogram. Conclusions: The PersonalRT27 is a novel tool that integrates clinical-pathological, molecular, and genetic parameters. External and independent validation will be required to implement its clinical use.
format	article
author	Inmaculada Beato Tortajada Carlos Ferrer Albiach Virginia Morillo Macias
author_facet	Inmaculada Beato Tortajada Carlos Ferrer Albiach Virginia Morillo Macias
author_sort	Inmaculada Beato Tortajada
title	Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
title_short	Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
title_full	Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
title_fullStr	Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
title_full_unstemmed	Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
title_sort	nomogram for the personalisation of radiotherapy treatments in breast cancer patients
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/34a937695973461ca48aa7a034ba64b6
work_keys_str_mv	AT inmaculadabeatotortajada nomogramforthepersonalisationofradiotherapytreatmentsinbreastcancerpatients AT carlosferreralbiach nomogramforthepersonalisationofradiotherapytreatmentsinbreastcancerpatients AT virginiamorillomacias nomogramforthepersonalisationofradiotherapytreatmentsinbreastcancerpatients
_version_	1718418214515376128

Nomogram for the personalisation of radiotherapy treatments in breast cancer patients

Ejemplares similares